{"eventGroups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.\n\nTotal-body irradiation: Undergo low-dose total-body irradiation\n\nFludarabine phosphate: Given IV\n\nAllogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation\n\nPeripheral blood stem cell transplantation: Undergo peripheral blood stem cell transplantation","id":"EG000","otherNumAffected":7,"otherNumAtRisk":12,"seriousNumAffected":2,"seriousNumAtRisk":12,"title":"Dose Level 1 (No Campath)"},{"description":"Patients receive alemtuzumab IV over 6 hours once daily on days -5 and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.\n\nAlemtuzumab: Given IV\n\nTotal-body irradiation: Undergo low-dose total-body irradiation\n\nFludarabine phosphate: Given IV\n\nAllogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation\n\nPeripheral blood stem cell transplantation: Undergo peripheral blood stem cell transplantation","id":"EG001","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Dose Level 2 (40mg Total Dose Campath)"},{"description":"Patients receive alemtuzumab IV over 6 hours once daily on days -6, -5, and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.\n\nAlemtuzumab: Given IV\n\nTotal-body irradiation: Undergo low-dose total-body irradiation\n\nFludarabine phosphate: Given IV\n\nAllogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation\n\nPeripheral blood stem cell transplantation: Undergo peripheral blood stem cell transplantation","id":"EG002","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Dose Level 3 (60mg Total Dose Campath)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Acute coronary syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":12,"numEvents":4},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Blood bilirubin increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Creatinine increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Hemolysis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Hypotension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Peripheral motor neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Ventricular arrhythmia"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Concurrent elevated bilirubin. Patient expired","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Respiratory failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Death due to GVHD"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Abdominal pain"}],"timeFrame":"AEs: Conditioning through Day 100; SAEs: Conditioning through Day 200"}